Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15:00 | Phathom Pharmaceuticals appoints Steven Basta as CEO | 1 | Seeking Alpha | ||
PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
14:59 | Phathom Pharmaceuticals Appoints Steven Basta To Succeed Terrie Curran As President And CEO | - | RTTNews | ||
14:17 | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
14:06 | Phathom Pharmaceuticals Announces Leadership Succession | 43 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
14:06 | Phathom Pharmaceuticals appoints new CEO | 1 | Investing.com | ||
Mo | Kenan Thompson kooperiert mit Phathom bei GERD-Behandlung | 1 | Investing.com Deutsch | ||
Mo | Kenan Thompson partners with Phathom for GERD treatment | 1 | Investing.com | ||
19.03. | Jefferies cuts Phathom Pharmaceuticals target to $13 | 1 | Investing.com | ||
11.03. | The Goldman Sachs Group Issues Pessimistic Forecast for Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price | 5 | MarketBeat | ||
07.03. | H.C. Wainwright maintains $28 target on Phathom Pharma stock | 1 | Investing.com | ||
06.03. | Phathom Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
06.03. | Stifel maintains Buy on Phathom stock with $28 target | 2 | Investing.com | ||
06.03. | Phathom Pharmaceuticals Non-GAAP EPS of -$0.79 beats by $0.29, revenue of $29.7M beats by $4.05M | 2 | Seeking Alpha | ||
06.03. | Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | 244 | GlobeNewswire (Europe) | VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3Over 300,000 filled... ► Artikel lesen | |
06.03. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
06.03. | Phathom Pharmaceuticals, Inc. - 10-K, Annual Report | - | SEC Filings | ||
24.02. | Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 | 2 | GlobeNewswire (USA) | ||
14.02. | Phathom spikes as Cantor Fitzgerald bullish on IP claims | 3 | Seeking Alpha | ||
07.02. | Stifel maintains $28 target on Phathom Pharmaceuticals stock | 2 | Investing.com | ||
23.01. | Phathom Pharmaceuticals COO Nabulsi verkauft Aktien im Wert von 51.956 US-Dollar | 1 | Investing.com Deutsch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 37,135 | +1,25 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
TEMPUS AI | 45,860 | -4,93 % | Decoding Tempus AI's Options Activity: What's the Big Picture? | ||
BIOAFFINITY TECHNOLOGIES | 1,005 | +265,45 % | RedChip Companies, Inc.: bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 14,190 | -10,81 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen | |
EVOTEC | 6,125 | +1,07 % | Evotec Aktie: Ratlosigkeit greift um sich? | News von Trading-Treff.de Der Hamburger Wirkstoffforschungsspezialist Evotec verzeichnet derzeit einen erheblichen Kursrückgang. Mit aktuell 6,05 Euro liegt die Aktie fast 4 Prozent unter dem Vortageswert... ► Artikel lesen | |
BIONTECH | 84,90 | +2,97 % | BioNTech-Aktie: Sie haben keine Ahnung! | News von Trading-Treff.de Für BioNTech ist aktuell der Trend nach unten gerichtet. Auch am Freitag ging es um über 1,2 % abwärts. Die Aktie war in den vergangenen Wochen schon der Katastrophe nahe.... ► Artikel lesen | |
BB BIOTECH | 31,900 | +0,31 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
BEAM THERAPEUTICS | 17,800 | -8,93 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,005 | -5,30 % | Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today | ||
SPRINGWORKS THERAPEUTICS | 41,290 | -6,48 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 18,740 | -2,88 % | Cantor Fitzgerald maintains Overweight on Summit Therapeutics shares | ||
GUBRA | 64,20 | +15,05 % | Gubra-Aktie +15%: Zeit fürs Comeback! | Die Gubra-Aktie ist in den letzten vier Wochen unter massiven Verkaufsdruck geraten und hat über ein Drittel ihres Wertes eingebüßt. Doch am Dienstagmorgen sendet das Papier des dänischen Biopharmaunternehmens... ► Artikel lesen | |
MODERNA | 25,220 | -3,78 % | Moderna-Aktie leicht im Minus (29,9070 €) | Der Anteilsschein von Moderna notiert heute ein wenig leichter. Der jüngste Kurs betrug 32,24 US-Dollar. Für der Anteilsschein von Moderna steht gegenwärtig ein Abschlag von 4,13 Prozent zu Buche. Die... ► Artikel lesen | |
IMMUNOVANT | 15,460 | -9,48 % | Immunovant Inc.: Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
GRI BIO | 2,255 | -29,53 % | GRI Bio, Inc.: GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan | Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA,... ► Artikel lesen |